Format

Send to

Choose Destination
Dig Liver Dis. 2015 Sep;47(9):811-4. doi: 10.1016/j.dld.2015.05.018. Epub 2015 May 24.

Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection.

Author information

1
I. Department of Internal Medicine, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany.
2
Institute for Interdisciplinary Medicine at the Asklepios Klinik St. Georg, Hamburg, Germany.
3
I. Department of Internal Medicine, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Infection Research (DZIF), Hamburg Site, Germany.
4
I. Department of Internal Medicine, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Infection Research (DZIF), Hamburg Site, Germany. Electronic address: j.schulze-zur-wiesch@uke.de.

Abstract

BACKGROUND:

There are only limited data on sofosbuvir-based treatment regimens in hepatitis C virus (HCV) genotype 4-infected patients.

AIMS:

To evaluate safety and efficacy of sofosbuvir-based triple-therapy in HCV genotype 4 infection.

METHODS:

All HCV genotype 4-infected patients who started sofosbuvir-based triple-therapy at our two centres between January and June 2014 were prospectively included (N=24) and compared to genotype 4 patients treated with peginterferon/ribavirin between January 2001 and December 2012 (N=63).

RESULTS:

The demographics in the sofosbuvir group and the controls were comparable (males 87.5% and 82.5%; mean age 46.7±9.0 years and 42.0±9.8 years, respectively). Sustained virological response was achieved in 83.3% in the sofosbuvir group and in 47.6% of controls (P=0.003). Fatigue (P=0.007), flu-like (P=0.015), gastrointestinal (P<0.001), dermatologic (P<0.001) and psychiatric symptoms (P=0.022) were more common in the control group.

CONCLUSIONS:

In our real-life cohort, sofosbuvir-based triple therapy confirmed its high efficacy and safety for chronic genotype 4 hepatitis C.

KEYWORDS:

Direct acting antivirals; HCV; SVR; Sustained virological response

PMID:
26091766
DOI:
10.1016/j.dld.2015.05.018
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center